Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors